Summit Therapeutics（SMMT）憑藉依沃西（Ivonescimab, AK112）與強大財務實力，展現投資潛力。依沃西在HARMONi-2三期試驗中PFS達11.14個月，優於Keytruda的5.82個月，降低49%疾病進展風險，有望成非小細胞肺癌一線治療，2025年初將啟動全球HARMONi-7試驗。公司現金儲備4.869億美元，新增2.35億美元融資，支撐多項三期試驗。與康方生物合作，獲北美、歐洲、日本市場權益，依沃西已於2024年5月及2025年4月獲中國NMPA批准兩項適應症，商業化加速。分析師給予買入評級，目標價31美元。儘管OS數據待2025年中公佈，依沃西的技術優勢和資金支持降低風險。SMMT適合看好生物科技的投資者，長期價值可期。我長期沽出其認沽期權做好！
| Side | Price | Filled | Realized P&L |
|---|---|---|
| Sell Open | 0.55 1Lot(s) | -- Closed |
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
- tiger_cc·2025-08-22數據勁爆！sell put坐等收錢LikeReport